

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 September 2024 (19.09.2024)



(10) International Publication Number
WO 2024/188803 A1

(51) International Patent Classification:
C12N 7/00 (2006.01) C12N 9/22 (2006.01)
C12N 7/02 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2024/056012

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(22) International Filing Date:
07 March 2024 (07.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23161210.2 10 March 2023 (10.03.2023) EP

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **BAVARIAN NORDIC A/S** [DK/DK]; Philip
Heymans Alle 3, 2900 Hellerup (DK).

(72) Inventors: **SCHWENEKER, Marc**; Eisenhutstr. 14f,
80689 Munich (DE). **HAUSMANN, Jürgen**; Alte Bun-
desstrasse 130, 79194 Gundelfingen (DE). **KALLA,**
Markus; Wölfl 6c, 82377 Penzberg (DE). **THRANE, Su-**
san Hoffmann; Bistrup Hegnsvej 7C, 3460 Birkerød (DK).
FALHOF, Janus; Windsorvej 25, 2300 København S
(DK). **HERTZ, Henrik**; Lidsovej 12, 2730 Herlev (DK).
ANDREA, Athina; Gråspurvevej 67, 1.3, 2400 København
NV (DK).

(74) Agent: **PREÜB, Ilka**; Bavarian Nordic GmbH, Fraunhofer-
strasse 13, 82152 Martinsried (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: PRODUCTION OF POXVIRUSES FROM QUAIL CELL CULTURES

(57) Abstract: The present invention relates to methods of producing poxvirus viral vector-based vaccine products from avian cell lines. In some embodiments, the avian cells are suspension quail cell lines. Pharmaceutical compositions such as vaccines produced by the methods of the invention are also provided. In some embodiments, the poxvirus viral vector is Modified Vaccinia Virus Ankara ("MVA") or recombinant MVA. In some embodiments, the recombinant MVA encodes heterologous antigens and can be used to produce a vaccine against the antigens. In some embodiments, the recombinant MVA encodes antigens of Respiratory Syncytial Virus (RSV) and the avian cells are used to produce a vaccine against RSV comprising the recombinant MVA and/or the encoded antigens.



WO 2024/188803 A1